Table 1.
Baseline characteristics of CCP with and without diabetes.
| CCP patients | No diabetes | Diabetes | p |
|---|---|---|---|
| N (%) | 438 (47.00%) | 494 (53.00%) | |
| Age (average ± SD) | 84.22 ± 10.6 | 81.16 ± 8.0 | <0.001 |
| Percentage >80 years old n (%) |
340 (77.6%) | 315 (63.8%) | <0.001 |
| Women n (%) | 236 (53.9%) | 252 (51.0%) | 0.394 |
| CCP criteria number (average ± SD) | 3.85 ± 1.26 | 3.86 ± 1.12 | 0.955 |
| Hypertension n (%) | 362 (80.4%) | 422 (85.4%) | 0.044 |
| Dyslipidemia n (%) | 195 (44.5%) | 326 (66.0%) | <0.001 |
| Atrial fibrillation n (%) | 176 (40.2%) | 149 (30.2%) | 0.002 |
| Ischaemic cardiopathy n (%) | 87 (19.9%) | 109 (22.1%) | 0.422 |
| Peripheral artery disease n (%) |
58 (13.2%) | 91 (18.4%) | 0.032 |
| Chronic kidney insufficiency < 30 mlClCr | 43 (9.8%) | 73 (14.7%) | 0.042 |
| Heart failure n (%) | 153 (34.9%) | 150 (30.4%) | 0.142 |
| Charlson score (average ± SD) |
2.05 ± 1.30 | 2.95 ± 1.30 | 0.015 |
| Stroke before CCP n (%) | 104 (23.7%) | 96 (19.4%) | 0.111 |
| Stroke after CCP n (%) | 36 (8.2%) | 30 (6.1%) | 0.249 |
| CHA2DS2VASC score (average ± SD) | 5.97 ± 2.38 | 7.14 ± 5.97 | <0.001 |
| HAS_BLED score (average ± SD) |
2.88 ± 1.14 | 3.10 ± 1.05 | 0.077 |
| Daily medications number (average ± SD) | 7.8 ± 3.29 | 9.80 ± 3.60 | <0.001 |
| Polypharmacy ≥ 4 n (%) | 392 (89.5%) | 484 (98%) | <0.001 |
| Polypharmacy ≥ 10 n (%) | 142 (32.4%) | 258 (52.2%) | <0.001 |
| Cognitive impairment n (%) | 179 (40.9%) | 159 (32.2%) | 0.006 |
| Pfeiffer test score (average ± SD) |
3.43 ± 3.39 | 2.72 ± 3.13 | 0.001 |
| Barthel score (average ± SD) | 62.8 ± 32.41 | 69.02 ± 31.28 | 0.003 |
| Barthel score < 60 n (%) | 182 (41.6%) | 161 (32.6%) | 0.005 |
| Fall risk n (%) | 103 (23.9%) | 85 (17.2%) | 0.018 |
| Gijón score (average ± SD) | 9.53 ± 5.12 | 10.46 ± 3.87 | 0.363 |
| Antiaggregant treatment n (%) |
147 (33.6%) | 238 (48.2%) | <0.001 |
| Anticoagulant treatment n (%) |
147 (33.6%) | 123 (24.9%) | 0.003 |
| Statin treatment n (%) | 149 (34.0%) | 274 (55.5%) | <0.001 |
| Proton pump inhibitor treatment n (%) | 285 (65.1%) | 358 (72.5%) | 0.016 |
| Selective serotonin reuptake inhibitors (SSRIs) n (%) | 131 (29.9%) | 149 (30.2%) | 0.943 |
| CNS depressant drugs n (%) | 249 (56.8%) | 265 (53.6%) | 0.356 |
| Death n (%) | 157 (35.8%) | 162 (32.8%) | 0.334 |